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1 INTRODUCTION 
1.1 Sepsis and Acute kidney Injury (AKI) 
 Sepsis and Septic Acute kidney injury (AKI) 1.1.1
With a yearly increasing incidence, sepsis is becoming  a major public health concern 
affecting approximately one million of patients and causing more than 200,000 
deaths per year in United States only [1].  It is now widely acknowledged that sepsis 
is caused by a dysregulated host response to infection, which ultimately leads to life-
threatening organ dysfunction. The clinical criteria to identify patients with sepsis 
consist of suspected or documented infection and an acute increase of ≥ 2 SOFA 
(Sequential Organ Failure Assessment Score) points. This definition, proposed at a 
task force meeting convened by national societies of Critical Care Medicine, 
abandoned the use of systemic inflammatory response syndrome (SIRS) criteria to 
identify patients with sepsis.  
The pathobiology of organ dysfunction in sepsis suggests a more complex sequel 
than infection plus accompanying inflammatory response alone and is consistent with 
the view that cellular defects underlie physiologic and biochemical abnormalities 
within specific organ systems [2]. Acute kidney injury (AKI) is a common and 
potentially fatal complication of sepsis that is associated with high morbidity and 
mortality in hospitalized patients, especially in the intensive care unit (ICU) [3]. Sepsis 
may cause AKI among critically ill patients in approximately 50% of cases [4]. Septic 
AKI is characterized by a rapid and often profound decline in renal function, usually 
evolving over hours to days after the onset of sepsis.  
 The pathophysiology of acute kidney injury (AKI)  1.1.2
The pathophysiology of AKI in sepsis is multi-factorial and consists of endothelial 
dysfunction, intrarenal hemodynamic changes, infiltration of inflammatory cells in the 
renal parenchyma, intraglomerular thrombosis, and obstruction of the tubules with 
necrotic cells and debris [5]. The innate immune response to infection triggers 
adaptive mechanisms affecting the kidney’s tubular, vascular and glomerular 
functions.  Essential for the innate immune response is the recognition of cellular 
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components or fragments of invading pathogens as well as components of damaged 
host cells or extracellular matrix generated during inflammatory stress. These so 
called pathogen-associated molecular patterns (PAMPs) and damage-associated 
molecular patterns (DAMPs) are recognized by pattern recognition receptors (PRRs) 
on immune cells [6]. Both PAMPs, e.g. lipopolysaccharide, lipoteichoic acid, 
peptidoglycan, lipopeptides, bacterial/fungal/parasitic DNA and viral RNA and 
DAMPs, e.g. heat shock proteins, fibrinogen, S 100 proteins are released in the 
circulation. As approximately one-fifth of the cardiac output is filtered by the kidney, 
renal cells in septic patients are continuously exposed to DAMPs and PAMPs, either 
via the blood or via its filtrate in the tubular lumen. Once PRRs on immune cells are 
triggered by PAMPs or DAMPs, the production of cytokines and chemokines is 
initiated evoking a systemic inflammatory response. In the kidney, and other affected 
organs, this is reflected by recruitment and mobilization of macrophages, natural killer 
cells and neutrophils (Figure 1).   
The production of pro-inflammatory cytokines by immune cells, mostly TNFα, IL-6 
and IL-1, to a large extent contribute to the progression of sepsis. This is amongst 
others appreciated by the fact that TNFα as a single factor can induce similar 
deleterious effects as endotoxin stimulation or sepsis itself [7]. TNFα causes renal 
damage by recruiting leukocytes, accelerating fibrin accumulation, promoting cell 
lysis and the release of vasoconstrictor substances [8]. Administration of anti-TNF 
monoclonal antibodies showed beneficial effects in numerous animal models of 
sepsis [9]. 
Also the local production of chemokines in the kidney plays a crucial role in the 
development and/or progression of AKI.  Among the chemokines produced in renal 
tissue, monocyte chemoattractant protein 1 (MCP-1, also known as CCL2), seems to 
be particularly increased in mouse models of LPS induced septic AKI and in human 
AKI patients. In line with this, urinary MCP-1 protein levels have been suggested as 
early novel biomarker of AKI [10]. Apart from attracting monocyte and neutrophils into 
the renal parenchyma, MCP-1 perpetuates inflammation by increasing the expression 
of the IL-6 and intercellular adhesion molecule-1 (ICAM-1) through the activation of 
the transcription factors such as NF-kB and AP-1 in human tubular epithelial cells 
[11] . 
Toll-like receptors (TLRs) are a family of single membrane-spanning receptors and 
belong to the so called PRR. TLRs are so far composed of 11 members in mammals 
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of which TLR4 seems to play an important role in septic AKI. TLR4 binds 
lipopolysaccharide (LPS) with high affinity and subsequent interacts with the myeloid 
differentiation protein 2 (MD2), which recognizes the Lipid A domain of LPS, to form 
an activated LPS-MD2-TLR4 homodimer. Once activated, the homodimer initiates an 
intracellular signaling cascades which result in the regulation of gene expression of a 
broad spectrum of genes involved in the defense against pathogens (e.g. TNFα, IL-6 
and IL-1) [12]. In order to limit exaggerating cytokine release in the circulation, 
modulation of the MD2-TLR4 interaction has been considered as a novel therapeutic 
target in the treatment of septic AKI. Indeed eritoran, a synthetic lipid A antagonist 
that blocks LPS from binding to MD2-TLR4, has shown protective effects in mice and 
rats by decreasing excessive inflammatory responses [13] [14] [15]. However, 
eritoran failed to reduce mortality rate in prospective, randomized, double-blind, 
multicenter phase 2 and 3 clinical studies [16, 17]. Natural products such as  
curcuma longa, sulforaphane and iberin, behave in a similar manner as eritoran and 
prevent binding of LPS to the MDR2-TLR4 complex [18].  
 
  
Figure 1 Sequel of events leading to septic acute kidney injury.  
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1.2 The role of tonicity response element binding protein (TonEBP/NFAT5) in 
inflammation 
Nuclear factor of activated T cells 5 (NFAT5), also known as tonicity response 
element binding protein (TonEBP), is a transcription factor and member of the family 
of Rel-like domain-containing factors including NF-kB and NFAT1-4. The 
physiological function of TonEBP/NFAT5 was initially described as a protective factor 
against osmotic stress in the renal medulla as it transcriptionally regulates the 
expression of numerous osmoprotective genes, e.g. Hsp70 and aldose reductase 
(AR). Apart from this, TonEBP/NFAT5 promotes cellular accumulation of major 
organic osmolytes by regulating the expression of plasma membrane transporters 
such as the sodium-chloride-betaine cotransporter (BGT1) and the sodium-myo-
inositol cotransporter (SMIT).  
NF-kB and NFATc are essential transcription factors in the innate immune response 
and are activated through the interaction of specific DAMPs and different types of 
PPRs. The NF-kB signal pathway can be activated by cell surface receptors (TLR, 
TNFR, EGFR), cysotoslic receptors (retinoic acid induced gene 1 (RIG-I)-Like 
receptors (RLRs), nucleotide binding oligomerization domain (NOD)-like receptors 
(NLRs)) and by the c-type lectin receptor families. In addition it can be activated 
independent of receptors by phorbol esters, UV light, ionizing radiation and reactive 
oxygen species (ROS) [19]. NFATc cannot be activated by TLRs but respond to the 
calcium mobilization-coupled receptors Dectin 1 and CD14 [20]. Although 
TonEBP/NFAT5 has approximately 40% sequence homology in the DNA binding 
domain with NFATc, it does not contain a calcineurin-depended regulatory domain 
[21]. In recent years, a variety of studies uncovered that TonEBP/NFAT5 plays 
important roles in the initiation and progression of inflammatory responses associated 
with changes in local and systemic osmolality [22] . Nonetheless, despite extensive 
studies the exact role of TonEBP/NFAT5 with respect to inflammation, NFAT5 is still 
fragmentary as compared to that of the NF-κB and NFATc proteins.  
Chronic inflammation and dysregulation of the immune system might partly underlie 
or perpetuate microvascular complications in diabetes. Hyperglycemia results in 
significant plasma hyperosmolarity in the range of 310-350 mOsm/kg H2O in diabetic 
patients. Yang B et al. reported that exposure of human peripheral blood 
mononuclear cells (PBMC) to hyperosmotic conditions (330-410 mOsm/kg H2O) 
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induce the expression of IL-1 and IL-8. Moreover, there were significant fold 
increases in DNA binding activities of TonEBP/NFAT5 to the tonicity elements OREB 
and OREC in PBMCs from patients with diabetic nephropathy compared to diabetic 
control subjects [23] . It also has been reported that hyperglycemia stimulates M1 
polarization and migration of macrophages via upregulation of TonEBP/NFAT5, that  
TonEBP/NFAT5 haplo-deficiency in a mouse model of DN reduced the number of 
renal macrophages and renal inflammation and that genetic variants within 
TonEBP/NFAT5 are associated with renal function, blood pressure, and systemic 
inflammation, thus supporting a role for TonEBP/NFAT5 in diabetic microvascular 
complications [24]. Madonna.R et al. reported that the induction of COX-2 in 
endothelial cells is at large regulated by TonEBP/NFAT5 as its disruption prevents 
hypertonicity-mediated induction of COX-2 [25] . 
Apart from being a transcription factor for hypertonicity regulated genes, several 
reports also indicate that TonEBP/NFAT5 may participate in the inflammatory 
response in the rheumatoid synovium independent of hypertonicity. TonEBP/NFAT5 
is not only highly expressed in the synovium but in synoviocytes its activity is 
increased by proinflammatory cytokines, such as IL-6 and TNFα. Silencing of 
TonEBP/NFAT5 is associated with a reduced CYR61, CCR2, TGFβ2 and TNFRSF 
expression [26], likewise is the expression of iNOS, IL-6, COX-2, TNFα, IL-12β 
diminished in TonEBP/NFAT5-/- bone marrow derived macrophages (BMDMs) in 
response to LPS as compared to that of TonEBP/NFAT5+/+ BMDMs [26]. Further 
analysis revealed that LPS-induced recruitment of TonEBP/NFAT5 to the iNOS 
promoter depends on inhibition of IĸB kinase β (IKKβ) activity and de novo protein 
synthesis, and is sensitive to histone deacetylation. An in vivo study showed that 
TonEBP/NFAT5 is essential for the immunity against Leishmannia major, which need 
TLR and iNOS expression in macrophage [27]. Similar as shown for renal 
macrophage infiltration in a model of DN, Halterman J et al. reports that 
TonEBP/NFAT5 haplo-insufficiency reduced the formation of atherosclerotic lesion by 
73%. In vitro studies revealed that TonEBP/NFAT5 is required for macrophage 
migration, which is an essential step in the progression of atherosclerosis [28]. 
Tellechea M et al. [65] studied the contribution of TonEBP/NFAT5 to macrophage 
functions in different polarization settings. They found that TonEBP/NFAT5 enhanced 
iNOS, IL-1β and IL-12β in M1 polarized macrophage, while it regulates markers of 
M2-polaized macrophages i.e. Arg1, CD163, YM-1 and Fizz-1. They concluded that 
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NFAT5 plays a predominant role in promoting proinflammatory macrophage 
functions.  
 
1.3 Carbon monoxide 
It is genuinely accepted that carbon monoxide (CO) is a poisonous gas at high 
concentration because of its strong affinity for haemoglobin and hemeproteins. In the 
last two decades this paradigm has been shifted as a large number of studies have 
demonstrated that CO, endogenously generated as a break-down product of heme, 
at low concentrations is a mediator of cell physiology and functions [29, 30]. 
Degradation of heme is catalyzed by heme oxygenases. Two isoforms (HO-1 and 
HO-2) are known which are encoded by two different genes (Hmox1 and Hmox2 
respectively) [31]. The inducible isoform HO-1 is ubiquitously expressed while the 
constitutively expressed HO-2 is primarily found in the vasculature and testis. Heme 
oxygenases are the rate-limiting enzymes in the conversion of heme to biliverdin, 
releasing CO and Fe2+ as by-products. Biliverdin is subsequently reduced to bilirubin 
by biliverdin reductase (figure 2). 
 
 
 
Figure 2 Endogenous Carbon Monoxide generation pathways. 
 
 
Like other gasotransmitters, CO can diffuse freely through cell membranes and 
rapidly interact with heme containing proteins. This may lead to changes in signal 
transduction in various ways. By interacting with the soluble guanylyl cyclase (sGC) 
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CO can increase cyclic GMP concentrations directly or indirectly by interacting with 
NO synthase (NOS) to activate the NO-cGMP pathway. This in turn may stimulate 
potassium channels and change the cellular ion-homoeostasis. CO can also interact 
with more distal targets like the heme-containing transcriptional factors BACH1 and 
NPAS2. Finally CO can modulate the production of mitochondrial superoxide by 
interfering with oxidative phosphorylation and electron transport and thus influences 
the activity of redox dependent transcription factors. 
Early studies on the biological properties of CO used CO in its gaseous form. As 
reported by Otterbein et al. CO inhalation (<250 ppm) improves survival rates in a 
model of LPS-induced endotoxemia in rats. This was accompanied by less severe 
lung alveolitis and reduced edema formation, and diminished iNOS expression in 
lung primary macrophages [32]. Improved survival rates for CO inhalation therapy 
have also been reported in a mouse model of cerebral malaria [33].  Even though CO 
inhalation seems to be an easy, straightforward and cost effective application, safety 
and practical issues constitute serious limitations. First of all, administration of CO in 
its gaseous form is problematic in clinical settings for outpatients. Moreover, no 
reliable methods have been established yet to achieve safe and effective tissue CO 
concentrations or to monitor CO toxicity. Despite the medical practice of monitoring 
CO intoxication by serum COHb, it is still not known if COHb constitutes the optimal 
measure for CO exposure and if COHb simply reflects CO intoxication. Experiments 
performed in dogs have revealed that dogs died with an average COHb level of 65% 
within an hour after administrated of 13% CO gas by inhalation. In contrast, severe 
anemic dogs that received a blood transfusion containing red blood cells with COHb 
levels of 80% survived indefinitely. Hence the authors postulated that for CO 
inhalation it is not the CO bound to hemoglobin that is toxic rather the fraction that 
escapes it [34]. This dissolved CO gas can subsequently penetrate the tissue and the 
cells and bind to intracellular targets, thus interfering with their biological activity. 
1.4 Carbon monoxide releasing molecules 
Based on the avid affinity of CO to transition metals, Motterlini and colleagues 
envisioned the development of transition metal carbonyls as prototypic carbon 
monoxide-releasing molecules (CORMs) [35] [36]. Since CORMs contain a transition 
metal surrounded by a certain number of carbonyl groups as coordinating ligands 
they are able to carry and deliver CO to biological systems. The first published 
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CORMs, using either manganese or ruthenium as transition metal, were only soluble 
in organic solvents (CORM1 and CORM2) [34]. Further optimization lead to CORM3 
which is soluble in aqueous solution and releases CO under physiological conditions 
[35]. Although CORM2 and CORM3 have been widely used in numerous studies to 
uncover the biological properties of CO [37-40], there are some concerns related to 
the use of these CORMs as therapeutic compound.  
Most of the published CORMs used in biological systems either spontaneously 
release CO when dissolved in aqueous solutions or require specific chemical or 
physical stimuli to favor CO dissociation from these complexes. Hence CO delivery is 
not target tissue specific as it can freely diffuse to other tissues. To avoid or to 
mitigate potential adverse effects of CO tissue specific CO delivery would be 
preferable. One way to meet this objective is allowing CO to be released only 
intracellularly through the action of cell specific enzymes. It should also be 
emphasized that for clinical applications ruthenium as transition metal for CORMs 
might not be an optimal choice since should be regarded as highly toxic [41]. To 
solve the problems related to ruthenium and other transition metals new approaches 
are on the verge. CORMs can be bound to macromolecular carriers, for example 
polymeric micelles, nanoparticles, copolymers and proteins, either by covalent 
binding or no covalent adhesion [42]. Although this to some extent solved the 
problem associated with the use the rare transition metals, these devices do not 
allow intracellular release of CO. With the development of acyloxybutadiene–Fe(CO)3 
complex the use of a transition metal common to the human body and intracellular 
delivery of CO was realized [39]. Acyloxybutadiene–Fe(CO)3 complexes are stable 
under physiological conditions but once inside the cell the ester functionality is 
cleaved off, subsequently the labile dienol–iron carbonyl complex disintegrates under 
oxidative condition to release CO, iron and corresponding enones. Since CO release 
from Acyloxybutadiene–Fe(CO)3 complexes are triggered by esterase activity, these 
complexes are also known as enzyme, or more precisely esterase triggered (ET)-
CORMs. In close collaboration with the groups of Prof. Schmalz (Organic chemistry, 
University of Köln), the Vth medical department have performed various studies 
describing the behavior of ET-CORMs in various biological settings [40, 41]. ET-
CORMs are capable to protect cells against cold inflicted injury, induce HO-1 
expression and suppress TNFα-mediated VCAM-1 expression [43, 44]. The 
biological properties of ET-CORMs are highly related to the type and complexity of 
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the ester-functionality. Also, its position in the (η4‐Diene) iron complex is pivotal for 
the kinetics of CO release. The simplest ET-CORMs are the 2-cyclohexenone 
derived ET-CORMs that contain an acetate as ester functionality either at the inner or 
outer position (figure 3). ET-CORMs seem to behave differently in endothelial as 
compared to epithelial cells, which might be explained by differences in the 
expression cell specific esterases.  
 
 
 
 
 
 
 
Figure 3 The chemical structure of ET-CORMs 
 
 
 
 
 
rac1 
2-cyclohexenone derived, inner position 
rac4 
2-cyclohexenone derived, outer position 
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Although ET-CORMs also have the disadvantage of not delivering CO in a strictly cell 
specific manner, these complexes paved the way for developing protease triggered 
CORM [45]. These CORMs are synthesized as tripartite compound consisting of a 
peptidase-specific (oligo-) peptide, a self-immolative linker attached to the 
cyclohexadiene-Fe(CO)3 moiety (figure 4).  
 
 
 
 
 
 
 
Figure 4 General design of protease-activated ET-CORMs 
 
 
Apart from the design for specific cell targeting of CO release, ET-CORMs can also 
be synthesized as so called bi-functional molecules. Drugs that carry a free carboxyl 
functionality can easily be coupled in a similar fashion as done for acetate. Since CO 
down-regulates inflammation, bifunctional ET-CORMs may display synergistic effects 
on inhibiting inflammation when an anti-inflammatory compound like nonsteroidal 
anti-inflammatory drugs (NSAIDs). Since NSAID are known to display adverse 
effects, e.g. serious gastrointestinal, hepatic, cutaneous and renal adverse events, 
synergy between NSAID and CO may lead to reduced therapeutic NSAID 
concentrations.  
In this doctoral thesis, we made use of a bifunctional ET-CORMs, consisting of 
monomethyl fumarate (MMF) as ester functionality. MMF-CORM can be synthesized 
with the ester either at the inner or outer position as described for other ET-CORMs 
(figure 5). Dimethyl fumarate was first licensed in Germany as oral therapy for 
psoriasis and later it was approved by US Food and Drug administration (FDA) and 
the European Medicines Agency (EMA) for treating relapsing multiple sclerosis. In 
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the small intestine dimethyl fumarate (DMF) is rapidly converted into its active 
metabolite, monomethyl fumarate (MMF) [46] [47]. Various studies have highlighted 
the therapeutical potential of DMF in a variety of animal models including Alzheimer’s 
disease [48], traumatic brain injury [49], allergic encephalomyelitis [50], liver 
ischemia/reperfusion injury [51] and cardiomyopathy in type 1 diabetes [52].  Other in 
vitro studies have reported an anti-oxidative and anti-inflammatory effect of DMF.  
 
 
 
Figure 5 The chemical structures of monomethyl fumarate, MMF-CORM-O and 
MMF-CORM-I. 
 
1.5 Aims of the study 
As mentioned above, sepsis may lead to organ dysfunction such as AKI. AKI not only 
is characterized by a decreased glomerular filtration rate (GFR) it also impairs the 
urinary concentration ability [53, 54]. The latter depends on the expression of various 
transporters and channels in medullary nephron segments. It is believed that is 
caused by an LPS mediated increase in medullary nitric oxide production by iNOS 
induction, which in turn results in impairment of the transcriptional activity of 
TonEBP/NFAT5 by S-nitrosylation and ultimately to a reduced expression of 
TonEBP/NFAT5 target genes required for urinary concentration. Yet it remains to be 
assessed to what extent inflammatory mediators, e.g. LPS, TNFα or IL-1, can 
influence activation of this transcription factor. Our hypothesis is that these mediators 
cannot activate TonEBP/NFAT5 and thus cannot compensate for the reduced 
transcriptional activity of TonEBP/NFAT5 in renal medullar cells. Since CO mitigates 
inflammation and has been reported to inhibit iNOS expression, CORM holds the 
promise of preventing renal complications in the course of sepsis. Because DMF is 
MMF-CORM-O 
 
MMF-CORM-I 
 
Monomethyl fumarate 
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effective in preventing oxidative stress and inflammation in septic rats [55] this also 
provides a rational for the use of bifunctional CORMs, i.e. MMF-CORM, to obtain 
possible synergistic effects. To test the hypothesis the following questions were 
addressed in this thesis: 
 
1. Is TonEBP/NFAT5 activated by mediators of inflammation, i.e. LPS and TNFα, 
in renal inner medullary collecting duct cells (miMCD cells). Does this result in 
regulation of TonEBP/NFAT5 target genes at the mRNA and protein level? 
2. Is TonEBP/NFAT5 activation involved in regulation of inflammatory mediators 
(cytokines and chemokines) in miMCD cells, murine macrophage (Raw264.7 
cell line) and isolated spleen cells from wild-type and TonEBP/NFAT5-/- mice?  
3. Does CO regulate TonEBP/NFAT5 activation in Raw264.7 cells? Does it 
influence iNOS and HO-1 expression? 
4. Is there synergy between CO and MMF in suppressing inflammation?  
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2 MATERIALS AND METHODS 
2.1 Materials 
 Chemicals 2.1.1
2.1.1.1 Commercial chemicals 
Table 1 Chemicals 
Chemicals Source 
β-alanine Sigma-Aldrich(germany) 
Acrylamidmix 40% Fluka(Swiss) 
Agarose (PAGE) Serva (Germany)  
Albumin standard (BSA)  Thermo Scientific™ (USA)  
Ampicillin  Bioline GmbH (Germany)  
APS  Sigma-Aldrich (Germany)  
CASY-ton Roche (Germany)  
Chemiluminescennce reagent Western Lightning™  Perkin Elmer (USA)  
Collagen 0,1%  Sigma-Aldrich (Germany)  
Collagenase (from Clostridium histolyticum) Type V  Sigma-Aldrich (Germany)  
DMEM/F-12, GlutaMAXGibco®  Invitrogen (Germany)  
DMSO  Sigma-Aldrich (Germany)  
DNA ladder buffer 10 x  Invitrogen (Germany ) 
DNA ladder generuler 1kb  Invitrogen (Germany)  
D-PBS 1 x Gibco®  
 
Invitrogen (Germany) 
DTT 0,1M  
 
Invitrogen (Germany)  
DTT 1M  
 
Invitrogen (Germany)  
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Endothelial cell growth medium, advanced  
 
Provitro (Germany)  
Ethanol 100%  
 
Sigma-Aldrich (Germany)  
Gel red Biotrend Germany 
Formaldehyde 37% Sigma-Aldrich (Germany)  
 
FCS  
 
Life Technologies 
(Germany)  
Gelatin from bovine skin  
 
Fluka (Swiss)  
Glycerol (99%)  
 
Sigma-Aldrich (Germany)  
Glycine  Sigma-Aldrich (Germany)  
Hydrogen chloride 1M  
 
Sigma-Aldrich (Germany)  
Isopropanol Merck (Germany)  
Lithium chloride Merck (Germany)  
 
Laemmli-buffer  
 
Biorad 
Lipopolysaccharides from E.coli O55:B5 
 
Sigma aldrich 
Magnesium chloride (MgCl2)  Fluka (Swiss)  
2-β-Mercapto ethanol  Sigma-Aldrich (Germany)  
Methanol  Carl Roth (Germany)  
Milk powder  
 
Fluka (Swiss)  
NaCl (sodium chloride)  
 
Merck (Germany)  
dNTP-Mix(dATP,dTTP,dCTP,dGTP) Carl Roth (Germany)  
PageRuler Plus Prestained Protein ladder  
 
Invitrogen (Germany)  
PBS 10 x  Invitrogen (Germany)  
Penicillin/streptomycin  Sigma-Aldrich (Germany)  
Phosphatase Inhibitor Cocktail 2  
 
Sigma-Aldrich (Germany)  
 
Phorbol 12-myristate 13-acetate  
 
Sigma-Aldrich (Germany)  
Poly-D-lysine hydrobromide  
 
Sigma-Aldrich (Germany)  
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Protease Inhibitor Cocktail Tablets  
 
Sigma-Aldrich (Germany) 
RNAse Inhibitor  
 
Roche (Germany)  
SDS  
 
Carl Roth (Germany)  
 
SiRNA NFAT5 EQ-009618  
 
DHarmacon (USA)  
 
TBE-buffer 10 x  
 
Invitrogen (Germany)  
  
 
TEMED Sigma-Aldrich (Germany) 
Ficoll-paque GE healthcare life 
science(UK) 
 
2.1.1.2  Chemicals preparations done in our laboratory 
Table 2 Chemicals preparations done in our laboratory 
Chemicals Ingredient 
ChIP cytosolic lysis buffer Tris pH 8 50mM, EDTA pH8 2mM, NP40 0.1%, glycerol 10% 
ChIP nuclear lysis buffer SDS 1%, EDTA pH8 5mM, Tris pH8 50mM 
Cytosolic extracts buffer A 100mM HEPES,PH 7,9,1M KCl, 1M MgCl2 ,0,5M 
EDTA ,100mM DTT and 200mM PMSF 
DB dilution buffer NP40 0.5%, NaCl 200mM, EDTA 5mM, Tris pH8 50mM 
EB-extraction buffer TE 1x pH8, SDS2% 
LiCl  washing Buffer SDS 0.1%, NP40 1%, EDTA 2mM, LiCl 500mM, Tris pH8 20mM 
NaCl washing Buffer SDS 0.1%, NP40 1%, EDTA 2mM, NaCl 500mM, Tris pH8 20mM 
Nuclear extract buffer B 100mM HEPES, PH 7,9,  80% glycerol, 2M NaCl, 
0.5M EDTA, 100mM DTT and 200mM 
PMSF,200mM Benzamidine and 5mg/ml 
leupeptin 
PBMC isolation buffer 1 x PBS and 3 mM EDTA 
TBS 50 mM Tris-Cl, pH 7.6; 150 mM NaCl 
Transfer buffer 25mM Tris, 192mM glycine, 15% methanol (PH 8.4) 
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 Antibodies 2.1.2
Table 3 Antibodies 
Antibodies Source 
Dilution 
In WB 
Company 
NFAT5 mouse 1:200 Santa Cruz         Sc-398171 
Histone 3 mouse 1:4000 Enzo life sciences #61476  
Beta actin mouse 1:20000 Santa cruz 
HO-1 rabbit 1:3000 Enzo life sciences ADI-SPA-895 
iNOS rabbit 1:200 Santa cruz Sc-651 
 
 Primers 2.1.3
Table 4 Primers  
Primers Sequence(5´→3´) Tm 
[oC] 
GC-
content 
NFAT5 
Forward 
5’- GTA ACC ATG ATT AGT CTT TTA GCT TTA 
TG -3’ 
 
59.6 oC 31% 
NFAT5 
Reverse 
5’- GTT ACC ATG ATT AGT CTT TTA GCT TTA 
TG -3’ 
 
58.9 °C 43.5% 
Cre 
Forward 
5’- GCC AGC TAA ACA TGC TTC ATC -3’ 
 
57.9 °C 47.6% 
Cre 
Reverse 
5’- ATT GCC CCT GTT TCA CTA TCC -3’ 
 
57.9 °C 47.6% 
TNFa 
Forward 
Forward:5’- CCC AAC TCT CAA GCT GCT  -3’ 
 
59.4°C 55%% 
TNFa 
Reverse 
Forward:5’- CCT CTG  AAA GCT GGG TGC-3’ 57.3°C 55% 
CCL2 
Forward 
5’- ATC TGGA GCT CAC ATT CCA-3’ 
 
54.3 °C 47.4% 
CCL2 
Reverse  
5’- TCC CTC TCA CTT CAC TCT GTCA-3’ 
 
60.3 °C 50% 
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 Kits 2.1.4
Table 5 Kits used in experiments 
Kits Source 
QIAquick Gel Extraction Kit  
 
Qiagen (Germany)  
 
GoTaq® DNA Polymerase Kit  
 
Promega (Germany)  
 
Genomic DNA isolation kit  
 
Promega (Germany)  
 
Coomassie(Bradford) Protein Assay kit Thermo  Scientific (Germany) 
 
 
 
 Consumables 2.1.5
Table 6 Plastic and other consumables 
Consumables Source 
Cell culture flasks Falcon™ 25 cm2 / 75 cm2  
 
BD Biosciences (USA)  
 
Cell scraper Falcon™  BD Biosciences (USA)  
Cryotubes Nunc™ 1.8 ml IVF CryoTube  Thermo Scientific™ (USA)  
Disposable cuvettes  Eppendorf (Germany)  
Disposable scalpel  Feather® (Japan)  
Disposable syringes  BD Biosciences (USA)  
Disposable pipette Falcon™ 1 ml/ 2 ml/ 5 ml/ 10 
ml/ 25 ml  
BD Biosciences (USA)  
Ependorf Safe-lock Tubes 0.5 ml / 1.5 ml / 2 ml  Eppendorf (Germany)  
Eppendorf epT.I.P.S 0.1-10 µl / 2-200 µl / 50-
1000 µl  
Eppendorf (Germany)  
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Falcon™ Tubes 15 ml / 50 ml  BD Biosciences (USA)  
Flat bottom plates Falcon™ 6 / 12 / 24 well  BD Biosciences (USA)  
Gel-Blotting-Paper (Filter paper)  Whatman® (England)  
“Mr. Frosty” Freezing Container Nalgene™  Thermo Scientific™ (USA)  
Parafilm® M  Bemis® (USA)  
Petri dishes Falcon™  BD Biosciences (USA)  
Polyethylen Film, Fisherbrand®  Fisher Scientific (Germany) 
PVDF-Membrane  Roche (Germany)  
Sterile filter (0.22 µm), Fisherbrand®  Fisher Scientific (Germany)  
White 96-well-plates  NUNC Denmark (USA)  
6-Tube Magnetic Separation Rack Cell signaling Technology( 
USA) 
 
 Machines or software used for experiments 2.1.6
Table 7 Machines and software 
Machines or software Source 
ABI step one plus Realtime PCR systems  Applied Biosystems® (USA)  
 
Autoclave Typ ELVC 5075  Systec GmbH (Germany)  
Bunsen burner Butane / Propan CV 470 Plus  Campinggaz® (Netherland)  
Cell counting CASY®  Schärfe Systems (Germany)  
CellF software Olympus (Germany)  
Centrifuge Biofuge Pico/ Fresco/ Primo R Heraeus (Germany)  
Centrifuge 5415/ 5417C  Eppendorf (Germany) 
DNA concentration measurement (Infinite® 200 
NanoQuant)  
Tecan (Germany)  
  
 
DNA Sequencing Analysis Software 5.2 Applied Biosystems 
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Electrophoresis horizontal chamber SUB-CELL®-
GT  
Bio-Rad Laboratories (USA) 
Electrophoresis  vertical chamber for western blot 
PAGE  
Biometra (Germany)  
ELISA Absorption measurement  Tecan (Germany)  
MagellanTM Data Analysis Software Tecan (Germany)  
GraphPad Prism 5.0  GraphPad Software, Inc (USA)  
Imaging system for blot  Biometra (Germany)  
Immunofluorescence optical microscopy   Olympus (Germany)  
Impulse Sealer  TEW(Taiwan) 
Incubator for Cell culture HERAcell 150i  Heraeus GmbH (Germany)  
Incubator and shaker Certomat® HK  B.Braun Biotech International 
(Germany)  
Light microscope DMIL  Leica (Germany)  
Microwave oven  Sharp (USA)  
Mini-PROTEAN® Tetra handcast systems Bio-Rad (Germany) 
Multi-pipette plus  Eppendorf (Germany)  
pH-Meter 538 Multical  WTW (Germany)  
PowerPacTM HV High-Voltage Power Supply Bio-Rad (Germany) 
Pipette Research Eppendorf (Germany)  
Refrigerator 4 °C  Liebherr (Germany)  
Refrigerator -20 °C  Liebherr (Germany)  
Refrigerator -80 °C  Liebherr (Germany)  
Shaker Unimax 210/ Rotamax 120/ Titramax 100  Heidolph (Germany)  
Shaker Vortex-Genie 2  Scientific Industries (USA)  
Shaker Vortex REAX 2000  Heidolph (Germany)  
Spectro-photometer U-2000  Hitachi (Japan)  
Sterile working bench for cell culture  Heraeus (Germany)  
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Thermo-cycler PCR 2720  Applied Biosystems (USA)  
Thermoblock TechneDri-Block® DB-2D  Biostep GmbH (Germany)  
‘‘The Imager Appligen‘‘ Software  OncorAppligene (USA)  
Trans-Blot® TurboTMTransfer System Bio-Rad (Germany) 
 
 
2.2 Methods 
 Cell culture 2.2.1
The miMCD-3 cell line (ATCC) is a mouse cell line with characteristics of mice inner 
medulla collecting duct cells. Cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 4,5g/L glucose, supplemented with 5% fetal calf serum, 
L-glutamine and penicillin (100u/ml)/streptomycin(100ug/ml). Mouse RAW 264.7  
macrophage cells  were grown in RPMI-1640 (Invitrogen ), supplemented with 10% 
heat-inactivated fetal calf serum and (100u/ml)/streptomycin(100ug/ml). Cells were 
cultured in a humidified atmosphere of 5% CO2 and 93% O2 at 37oC. Cells were 
grown in 6-wells plates to confluency. Medium osmolarity was adjusted by addition of 
NaCl (table 8). Medium osmolarity was checked using an osmometer. 
 
Table 8 Osmolality increased by addition of NaCl as endconcentration 
                 NaCl (mM)                            Osmolality (mOsm) 
25 300 
75 400 
150 500 
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 Monocyte isolation from Buffy Coat  2.2.2
2.2.2.1 Isolation of peripheral blood mononuclear cells (PBMCs) using Ficoll-
PaqueTM 
Fresh Buffy coat was got from German red cross blood bank. 
Dilute cells with 4 x the volume of buffer PBS+(1 x PBS plus 3mM EDTA), carefully 
layer 30 ml of diluted cell suspension over 15 ml of Ficoll-Paque in a 50 mL falcon 
tube. Centrifuge at 400xg for 30-40minutes at 20oC in a swing-out-bucket rotor 
without brake. Aspirate the upper layer leaving the mononuclear cell layer ( 
lymphocytes, monocytes, and platelets undisturbed at the interphase.  
Carefully transfer the mononuclear cell layer to a new 50ml falcon tube. Fill the tube 
with buffer until 50ml, mix and centrifuge at 300xg for 10 min at 20oC. To remove the 
red blood cells, the red blood cells were resuspended in 10ml RBC lysate solution 
and incubated in Room temperature for 8 min, filled up with PBS to 50ml with PBS+ 
and centrifuged at 200xg for 10 min at RT. For removal of platelets, resuspended the 
cell pellet in 50ml of PBS (2mM EDTA) buffer and centrifuged at 200xg until the 
supernatant was clear after centrifugation. Resuspended cell pellet in 40 ml buffer 
and cell count was performed using CASY.  
2.2.2.2 CD14+ monocytes were isolated from PBMC by positive selection using 
a MACS system (Miltenyi Biotech, Bergisch Gladbach)  
CD14+ monocytes isolation was performed according to manufacturer instructions. 
PBS++ (2mM EDTA+0,5%BSA) was used throughout the whole procedure. Per 107 
cells 80 µl PBS++ and 20 µl CD14 microbeads were added and incubated for 15 min 
at 4°C.Cells were washed with 1ml PBS++ per 107cells, centrifuged at 300g for 
10min and were resuspended in 500µl degassed PBS++ per 107 cells. During 
magnetic separation degassed PBS++ was used. Magnetic separation was 
performed by rinsing a LS column with 3 ml PBS++, the cell suspension was applied 
to the column and washed three times with 3 ml of PBS++. The LS column was 
removed from the MACS Magnet and the CD14+ cells were immediately flushed out 
with 5ml PBS++. Enriched CD14+ monocytes were counted by using CASY and used 
in subsequent experiments. 
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 Preparation of Nuclear and cytosolic extracts 2.2.3
The miMCD3 cells were cultured as described previously (2.2.1) and grown on T25 
flask until confluent. Cells were scraped off the bottom and transferred to 10ml falcon 
tube, and then spun at 2000 rpm. Cell pellets were homogenized in lysis buffer A 
100µl per 2×107 cells and incubated on ice 15min. Added 10% IGEPAL 12.5ul per 
100µl buffer A and then vortex for 10 sec. The cell extract was immediately spun at 
15,000 rpm for 1min, and the supernatant was collected as cytosolic extract. The 
pellet was resuspended in the buffer B and incubated on ice for 30 min while 
shaking, and then centrifuged at 15,000 rpm for 5 min at 4ºC. The supernatant was 
collected as nuclear extract and used in the subsequent experiment.  
 Westernblotting   2.2.4
Preparation of total protein, cytosolic and nuclear extract was performed as described 
at 2.2.3 and the concentration was determined using Coomossine (Bradford) protein 
assay kit. All standard and samples were triplicates. Pipetted 5µL of each standard 
and samples into the 96-well microplates, and then added 250 µL of the Coomassie 
Reagent to each well and incubated plate for 10 mins at room temperature. 
Measured all samples using TECAN infinite 200 with 595nm absorption wavelength. 
Prepare a standard curve by plotting the average blank-corrected 595nm 
measurement for standards versus its concentration in µg/mL. The three-parameter 
curve was employed to determine the protein concentration of each samples. Protein 
samples (15µg in 15µl), in the presence of laemmli buffer (1:4 diluted in laemmli 
buffer) were boiled for 10 min and cooled down on ice for another 10 min. Samples 
were shortly centrifuged down and then loaded on a sodium dodecyl sulfate-
polyacrylamide gel electrophoresis polyacrylamide (SDS-PAGE) gel. 
Stacking and separating gels for SDS-PAGE were made as below: 
Table 9 Gels formula for Westernblotting 
Ingredient Separate gel (10%) Stack gel 
ddH2O 4.8ml 3.6ml 
40 % Acrylamid  2.5ml 0.62ml 
Tris-buffer  2.5ml (1.5mmol/L) 0.63ml 
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10 % SDS  0.1ml 0.05ml 
TEMED 0.004ml 0.005ml 
10%APS 0.1ml 0.05ml 
 
All samples in the SDS-PAGE gel run at 200V for 50 min using Mini-PROTEAN® 
Tetra handcast systems and afterwards transferred to polyvinylidene fluoride (PVDF) 
membranes employing Trans-Blot® TurboTMTransfer System for 30 min. The 
membranes were then incubated for 1h in TBS containing 0.1% Tween-20 and 5% 
milk. The protein was then immunelabeled using specific primary antibodies which 
diluted in 5% milkpowder TBST (1%) solution at 4ºC overnight. The bound primary 
antibodies were detected using secondary antibodies diluted in 5% milkpowder TBST 
(1%) solution for 1 hour at room temperature after washing TBST buffer for 3 times. 
Detection of immune reactive bands was performed by enhance luminol reagent and 
visualized by chemiluminescence. 
 Real-Time Polymerase Chain Reaction (PCR) analysis   2.2.5
2.2.5.1 Total RNA Isolation with TRIzol™ reagent 
The cells were cultured and grown on 6-well flask until confluent. Washed all the 
samples with 1×PBS for 3 times, added 1 ml TRIzol™ Reagent per well and the cells 
were homogenized by pipetting up and down. Homogenized solutions were 
incubated in room temperature for 10 min to permit complete dissociation of the 
nucleoprotein complex.  Add 0.2mL of chloroform and shake samples vigorously for 
15 sec. After incubation for 2 mins, centrifuge all samples for 15 mins at 12,000 × g 
at 4 °C. Transfer the aqueous phase containing the RNA to new tubes. Added 0.5mL 
of isopropanol to the aqueous phase and incubate for 10 mins. Afterwards, centrifuge 
for 10 minutes at 12,000 ×g at 4 °C. Total RNA precipitated forms a white gel-like 
pellet at the bottom of the tube. Discard the supernatant with a micropipettor. 
Resuspended the pellet in 1mL of 75% ethanol and mix by inversing. Centrifuge 
samples at 7500 ×g at 4°C. Discard the supernatant with a micropipette and air dry 
the RNA pellet for 5-10mins. Dilute the RNA Pellet in 20-30µL Nuclease free water. 
Concentration of RNA determined by measuring absorbance at 260nm using the 
formula A260 x dilution x 40 = µg RNA/ml. 
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2.2.5.2  cDNA Reverse Transcription  
Used 1 µg total RNA per 20 µL reaction. 
 Prepared the 2 x RT master mix per 20µl reaction referring to the table below. All 
procedures performed on ice. 
Component Volume/Reaction(µL) 
10 x RT Buffer 2.0 
25 x dNTP Mix (100mM) 0.8 
10 x RT Random Primers 2.0 
MultiScrie TM Reverse Transcriptase 1.0 
RNase Inhibitor  1.0 
Nuclease-free H2O 3.2 
 
Prepared the cDNA RT reactions by pipetting 10µL of 2X RT master mix into each 
well in to PCR tubes and 10 µL of RNA sample into each well subsequently by 
pipetting up and down two times to mix. Seal the tubes and briefly centrifuge the 
tubes to spin down the contents and to eliminate any air bubbles. Placed the tubes in 
PCR machine and started the thermal cyclers using the thermal conditions in table 
below: 
Temperature(°C) 25 37 85 4 
Time 10 min 120 min 5 min ∞ 
 
Store the cDNA products in -20 °C until next step experiments. 
2.2.5.3 Taqman Assay 
All procedures were performed on ice. 
For each sample, pipet the following into a nuclease free 1.5-ml microcentrifuge tube, 
each samples in three replicates as well as endogenous controls and no template 
controls  
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PCR reaction mix component Volume per 20µL reaction (µL) 
for 3 replicates 
20x TaqMan® Gene Expression Assay 2.0 
2x  TaqMan® Gene Expression Master Mix 40.0 
cDNA template  4.0 
RNase-free water 34.0 
 
Vortex the PCR reaction mix component for several times. Transferred 20 µL of PCR 
reaction mix into each well of 96-well plates. Seal the plates with the appropriate 
cover and centrifuged the plate briefly. 
Loaded the plate into the ABI StepOneTM plus RT-PCR machine and run the fast 
program showed in bellowed table. 
 
Thermal cycling conditions 
Stage Temperature (°C) Time(mm:ss) 
Hold 50 2:00 
Hold 95 10:00 
Cycle 
(40 Cycles) 
95 0:15 
60 1:00 
 
Table 10 Plate experiment parameters for TaqMan® Gene expression Assays 
Measured Cycle threshold (Ct) values were normalized with beta-2-microglobulin and 
they were expressed as fold-over control samples. 
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  Chromatin immunoprecipitation assay 2.2.6
2.2.6.1 Nuclei preparation and chromatin digestion 
The miMCD cells were grown in T75 flasks until 70% confluent and then stimulated 
with LPS (1µg/mg) and NaCl (500mOsm) respectively. Fixation was performed at 
different time points, for example, 2h and 4h. Afterwards, 1% formaldehyde at room 
temperature for 10 mins and was quenched by TRIS 7.5 at final concentration of 
125mM for 5 mins. After washing the cells with ice-cold PBS for 3 times, Collect the 
cells into a 15 ml falcon tube by scraping with PBS.  Cell was spin down at 2000x 
rmp for 10 min and lysed in 600µL Buffer A (see in material) with protease and 
phosphatase inhibitors and 2 mM DTT for 5 min. centrifuge the samples at 3000xrmp 
for 5 min at 4°C. Collect the supernatant as cytoplasmic fraction and resuspend the 
pellet in 500 µL Buffer B (see in material) with protease and phosphatase inhibitors 
and 2 mM DTT. Furthermore, Cell lysates were sonicated ( Bioruptor®Plus) for 30 
cycles of 30s on plus 30s off. 
 Chromatin fragment sizes were always tested after each sonication as the followed 
procedures: 20 µL sonicate samples plus 280 µL DB buffer incubated at 65°C 
overnight while shaking at 200x rpm. The second day added 2 µL of 1mg/ml RNase 
A and incubate at 37°C for 1 hour and then add proteinase K (100 µL) and  incubate 
at 50°C for 1 hour while shaking at 200x rpm. Isolate DNA using QIAquick Gel 
Extraction Kit and load 300ng purified DNA samples on a 1% agarose gel and then 
run the electrophoresis with a 100 bp DNA marker. Properly digested chromatin 
ranging from 150 to 500 base pairs (bp) showed in the bellowed figure (Figure 6). 
                      
Figure 6 Properly digested chromatin migrates between 150-500 bp 
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2.2.6.2 Chromatin Immunoprecipitation and DNA purification 
Each sample was diluted 10x in dilution buffer for immunoprecipitation. Pre-samples 
were incubated with 30 µL Chip-Grade Protein G magnetic beads per each IP 
reaction and incubate 2h at 4°C in rotation. Pellet protein G magnetic beads in each 
immunoprecipitation by placing the tubes in a Magnetic Separation Rack. Waited 1 
min for solution to clear and then carefully transferred the supernatant to a new tube.  
Took 200 µL each sample as 10% Input and store at -80°C. Added 2µg antibody per 
IP and rotated samples overnight at 4°C. The second day added 30 µL protein-G 
magnetic beads per IP and rotated for 2 hours at 4°C. Pellet protein G magnetic 
beads by placing the tubes in a Magnetic Separation Rack and removed the 
supernatant carefully. Washed pellet protein G magnetic beads by adding 800 µL 
NaCl-washing buffer for 5 min on ice for 3 times. Washed pellet protein G magnetic 
beads with LiCl- washing buffer for 5 min on ice for 3 times. After the last washing 
procedure, aspirated the supernatant as much as possible and immediately added 
100 µL EB-extraction buffer at room temperature for 30 min with gentle vortex (1,200 
rmp). Pellet protein G magnetic beads by placing the tubes in a Magnetic Separation 
Rack and waited 1 min for solution to clear. Carefully transferred eluted chromatin 
supernatant to a new tube. To all samples, including 10% input samples, reversed 
cross-links by incubating at 65°C overnight while shaking at 200x rpm. The second 
day added 2 µL of 1mg/ml RNase A and incubate at 37°C for 1 hour and then added 
proteinase K (100 µL) and  incubated at 50°C for 1 hour while shaking at 200x rpm. 
Isolate DNA using QIAquick Gel Extraction Kit and get 20 µL purified DNA in the end. 
2.2.6.3 Quantification of DNA by SYBR-Green PCR: 
Added 2 µL of the DNA samples to each tube. 
Prepared the master reaction mix as described below. Added enough reagents for 
two extra reactions to account for loss of volume. Added 18 µL of reaction mix to 
each PCR reaction well. 
Reagent Volume for 1 PCR reaction 
Nuclease-free H2O 6 µL 
Primers 2 µL 
SYBR-Green Reaction Mix 10 µL 
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Started the following PCR reaction Program: 
a Initial denaturation 95°C 3min 
b Denature 95°C 15sec 
c Anneal and extension: 60°C 60sec 
d Repeat steps b and c for a total of 40 cycles  
 
Analyze quantitative PCR results and aciculate the IP efficiency manually using the 
percent Input Method and the equation shown below. 
Percent Input=10% x 2(CT 10% Input Sample –CT IP Sample) 
 
 ELISA 2.2.7
Cell culture supernatant was harvest at different time points after onset of stimulation 
and was stored in -80°C until analysis. TNFα, IL-10 and CCL-2 protein in supernatant 
were measured by ELISA (R&D systems) kits. All reagents and samples were 
brought to room temperature before use. All samples, standards and controls be 
assayed in triplicate. The optical density was measured by microplate reader set to 
450nm for absorption wavelength and 570nm for correction wave length. Megllan 
software were employed to analysis the readings and calculate the samples’ 
concentrations.  
 Cre+ NFAT5 flx/flx  conditional knockout mice and  murine splenocytes 2.2.8
isolation. 
Cre+ NFAT5 flx/flx  conditional knockout mice were described previously [56]. Mice was 
feed by tamoxifen diet for 4 weeks since 8-week-old and then been sacrificed using 
cervical dislocation method. One small piece of tail was dissected for the further 
genomic DNA isolation. 
Mice were fixed on a clean dissection board and abdominal area was rinsed with 
70% reagent alcohol. Abdominal cavity was incised and spleen was removed gently, 
which is located to the left side of the abdomen and inferior to the stomach, to the 
labeled 50ml falcon tube containing PBC with 2mM EDTA. Animal carcass was 
disposed in an appropriate freezer and stored at -20°C for disposal service pick up.  
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All procedures below were performed in the laminar flow hood. The isolated spleen 
was sliced into small pieces and places on the strainer attached to a petri dish. 
Remove the plunger form a 10-ml syringe and use the black rubber end to press the 
spleen. Firstly, press the spleen roughly through the strainer of larger mesh size 
(180nm) and wash the cells with the excess PBS, secondly, collect the filtration 
solution and press them through the strainer of small mesh size (50nm) and wash 
them again, thirdly collect the filtrated solution and transfer to the 50ml falcon tube. 
Centrifuge the cell suspension at 300g for 5 minutes and aspirate the supernatant. 
Suspend the cell pellet in cell culture medium (RIPM 1640 +10% FCS+P/S) for the 
further experiments. 
 Statistics 2.2.9
Quantitative data are depicted as mean ± SEM.  One way ANOVA was used to 
compare differences between control and treatment and Two-way ANOVA was used 
to compare differences between groups. Significance was defined according to a p 
<0.01. Statistical analyses were performed with GraphPad Prism 7.0 (GraphPad 
software, Inc. La Jolla. California, USA). 
 
Results 
33 
3 RESULTS 
3.1 Inflammatory conditions fail to induce NFAT5 nuclear accumulation in 
mouse inner medulla collecting duct cells (miMCD cells) 
 Although a variety of studies have shown activation of NFAT5 by pro-inflammatory 
stimuli in immune cells, it is currently not clear to what extent NFAT5 becomes 
activated in the inner medulla collecting duct under inflammatory conditions. We 
therefore investigated if LPS and TNFα, either alone or under hypertonic conditions, 
promote nuclear accumulation of NFAT5 in miMCD cells. As depicted in Figure 7, 
nuclear accumulation of NFAT5 was already evident 2 hrs after subjecting miMCD 
cells to hypertonic conditions. While 300 mOsm/kg H20 alone or in combination with 
LPS, did not result in nuclear NFAT5 accumulation, it was clearly detected in 
westernblot at 500 mOsm/kg H20 (figure 7A). To exclude that LPS concentrations 
were too low for NFAT5 activation, also 1 and 5 µg/ml of LPS were tested but 
likewise failed to increase nuclear NFAT5 expression (figure 7B). Under hypertonic 
conditions nuclear NFAT5 expression strongly increased at 24 hrs, without 
synergistic effects of LPS. The addition of TNFα also did not result in nuclear NFAT5 
accumulation, when applied alone or in combination with 500 mOsm/kg H2O (figure 
7C). This was also found for early time points when using higher TNFα 
concentrations (ranging from 12.5 to 100 ng/ml) (figure 7D).  
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Figure 7: Nuclear NFAT5 accumulation in response to hypertonic conditions and 
inflammatory stimuli in miMCD cells. (A) miMCD cells were stimulated for 2 hrs with 
different concentrations of NaCl (25 and 100 mM) resulting in isotonic or hypertonic 
conditions (300 and 500 mOsm/Kg H2O). Similar as described above miMCD cells were also 
stimulated with NaCl in the presence of LPS (10 ng/ml). Nuclear extracts were prepared as 
described in the methods and subjected to SDS-Page and Westernblotting.  (B) NFAT5 
expression was also tested in Westernblot using nuclear extracts obtained from miMCD cells 
stimulated for 12 hrs using higher concentrations of LPS (1 and 5 µg/ml). (C) Similar to LPS, 
TNFα was not able to activate NFAT5. No synergy between hyperosmotic conditions and 
TNFα or LPS stimulation were noticed. (D) TNFα stimulation also did not result in nuclear 
NFAT5 accumulation assessed 12 hrs after addition of TNFα.  
 
 
3.2 Inflammatory conditions fail to increase NFAT5 mRNA transcription. 
The NFAT5 protein regulates gene expression by binding to TonEBP consensus 
sequences in promoter regions. Since the promoter of NFAT5 also contains such 
sequences, NFAT5 transcriptional activity is expected to increase under hypertonic 
conditions [57]. There is however only limited data available as to whether 
inflammatory mediators have the propensity to regulated NFAT5 mRNA transcription. 
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Indeed we observed that NFAT5 transcription is upregulated by hypertonicity in a 
time- and dose-dependent manner (figure 8 A and B). In contrast, NFAT5 mRNA 
transcription was neither affected by LPS (figure 8C) nor by TNFα (data not shown). 
We also did not observe synergy between hypertonicity and LPS (figure 8D).  
 
 
Figure 8: NFAT5 mRNA expression in miMCD cells in response to hypertonicity and 
LPS stimulations. (A) miMCD cells were stimulated for 8 hours with isotonic - (300 
mOsm/kg·H2O) or hypertonic (400 or 500 mOsm/kg·H2O) NaCl concentrations (filled bars). 
miMCD cells cultured in normal medium served as control (open bar). (B) miMCD cells were 
stimulated with a hypertonic (500 mOsm/kg·H2O) NaCl concentration for different time 
periods (filled bars). miMCD cells cultured in normal medium served as control (open bar). 
(C) miMCD cells were stimulated for 8 hours with different concentrations of LPS (1 - 1000 
ng/ml) (filled bars). miMCD cells cultured in normal medium served as control (open bar). (D) 
miMCD cells were stimulated for 8 hours with hypertonic (500 mOsm/kg·H2O) NaCl 
concentrations alone or in combination with 10 ng/ml of LPS (filled bars). miMCD cells 
cultured in normal medium or stimulated with LPS alone served as controls (open bars). For 
A-D total RNA was isolated to assess NFAT5 mRNA by qPCR analysis as described in the 
methods. Data are normalized to ß2-microglobulin and expressed as mean NFAT5 mRNA 
level ± SEM relative to control unstimulated cells. *: P<0.01 (by one-way ANOVA), ns: not 
significant. 
3.3 Hypertonic NaCl concentration increase the expression of pro-
inflammatory cytokines in an NFAT5 dependent manner  
Both the CCL2 and the TNFα gene contain TonEBP concensus sequences [58], we 
therefore assessed if miMCD cells exposed to hypertonicity (400 and 500 
mOsm/Kg·H2O, 75 and 100 mM NaCl respectively) induce CCL2 or TNFα mRNA 
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expression as compared to cells that remained under isotonic (300 mOsmo/kg·H2O, 
25 mM NaCL) conditions. As illustrated in figure 9, hypertonicity increased CCL2 and 
TNFα mRNA expression in a dose- (figure 9 upper panels) and time-dependent 
manner (figure 9 lower panels). For both, mRNA expression increased already at 
early time point reaching a peak value 8 hrs after stimulation and gradually declined 
at 24 hrs.  
 
 
 
Figure 9: Hypertonic NaCl concentration increase the expression of pro-inflammatory 
Upper panels: miMCD3 cells exposed for 8 hrs to different hypertonic (300 – 500 mOsm/kg 
H2O) NaCl concentrations (25 – 100 mM NaCl) (filled bars). Lower panels: miMCD3 cells 
exposed to hypertonic (500 mOsm/kg H2O) conditions for different time periods (filled bars). 
mRNA expression of CCL2 (panels to the left) and TNFα (panels to the right) were assessed 
by qPCR analysis as described in the methods. Data are normalized to ß2-microglobulin and 
expressed as mean CCL2 or TNFα mRNA level ± SEM relative to control unstimulated cells 
(open bars). *: P<0.01 (by one-way ANOVA), ns: not significant  
 
To formally demonstrate that NFAT5, CCL2 and TNFα were transcriptionally 
regulated by NFAT5, miMCD cells were transfected with NFAT5 or scrambled siRNA 
and subsequently exposed for 8 hours to hypertonic (500 mOsm/Kg H2O) NaCl 
concentrations (figure 10). While in control (scrambled) siRNA transfected cells 
hypertonicity resulted in upregulation of NFAT5, TNFα and CCL2 mRNA expression, 
this was significantly blunted in NFAT5 siRNA transfected cells (figure 10 panels to 
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the left). In line with this TNFα and CCL2 concentrations in supernatants of these 
cells were significantly decreased (figure 10, panels to the right).  
 
 
 
Figure 10: NFAT5 is required for the expression of CCL2 and TNFα in response to 
hypertonic NaCl concentrations. miMCD cells were transfected with NFAT5 (hatched bars) 
or scrambled siRNA (filled bars) and subsequently exposed for 8 hours to hypertonic (500 
mOsm/Kg H2O) NaCl concentrations. mRNA expression of NFAT5, CCL2 and TNFα was 
measured by Taqman qPCR (panels to the left). Data are normalized to ß2-microglobulin and 
expressed as mean NFAT5, CCL2 or TNFα mRNA level ± SEM relative to control 
unstimulated cells (open bars). CCL2 and TNFα concentrations were also assessed in the 
supernatants of the cells by ELISA (panels to the right) *: P<0.01 (by one-way ANOVA).  
3.4 LPS-induced pro-inflammatory cytokines expression in miMCD cells is 
mediated by NFAT5 
Although LPS did not result in nuclear NFAT5 accumulation as measured by 
westernblotting, it cannot be ruled out that small amounts of nuclear NFAT5 regulate 
TNFα and CCL2 expression in a concerted action with other transcription factors 
(e.g. NF-κB). We therefore first performed dose and time response experiments with 
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LPS to assess the optimal conditions (time and dose) for LPS stimulation in 
subsequent experiments using NFAT5 siRNA transfected cells. As shown in figure 
11, CCL2 and TNFα mRNA transcription was detected at concentrations equal to or 
above 10 ng/ml of LPS (figure 11 upper panels). CCL2 and TNFα mRNA 
transcription displayed a similar kinetic as described for NaCl stimulation (figure 11 
lower panels). 
 
 
Figure 11: TNFα and CCL2 expressions in IMDC3 cells in response to LPS stimulation.  
Upper panels: miMCD3 cells were stimulated for 8 hours to different concentrations of LPS 
(1 -1000 ng/ml) (filled bars). Lower panels: miMCD3 cells were stimulated for different time 
periods with 10 ng/ml of LPS (filled bars). mRNA expression of CCL2 (panels to the left) and 
TNFα (panels to the right) were assessed by qPCR analysis as described in the methods. 
Data are normalized to ß2-microglobulin and expressed as mean CCL2 or TNFα mRNA level 
± SEM relative to control unstimulated cells (open bars). *: P<0.01 (by one-way ANOVA), ns: 
not significant. 
 
 
Next we assessed to what extent NFAT5 is involved in the regulation of CCL2 and 
TNFα. To this end, we stimulated NFAT5 or scrambled siRNA transfected cells for 8 
hours with 10 ng/ml of LPS. As depicted in figure 12, NFAT5 mRNA expression was 
not influenced by LPS in control siRNA transfected cells, but was slightly inhibited by 
LPS in NFAT5 siRNA transfected cells. In contrast, CCL2 and TNFα mRNA 
expression strongly increased upon LPS stimulation in control (scrambled) siRNA 
transfected cells, which was significantly blunted in NFAT5 siRNA transfected cells 
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(figure 12 panels to the left). CCL2 and TNFα concentrations in the supernatants of 
these cells decreased in parallel (figure 12, panels to the right).  
 
 
Figure 12: NFAT5 is required for the expression of CCL2 and TNFα in response to LPS. 
miMCD cells were transfected with NFAT5 (hatched bars) or scrambled siRNA (filled bars) 
and subsequently stimulated for 8 hrs with 10 ng/ml of LPS. mRNA expression of NFAT5, 
CCL2 and TNFα was measured by Taqman qPCR (panels to the left). Data are normalized 
to ß2-microglobulin and expressed as mean NFAT5, CCL2 or TNFα mRNA level ± SEM 
relative to control unstimulated cells (open bars). CCL2 and TNFα concentrations were also 
assessed in the supernatants of the cells by ELISA (panels to the right).  *: P<0.01 (by one-
way ANOVA), ns: not significant. 
 
3.5 Synergy between LPS and hypertonic NaCl concentration on CCL2 and 
TNFα expression 
Since LPS is known to activate the transcription factor NFκB while hypertonicity leads 
to activation of NFAT5 we assessed if there was synergy in the regulation of CCL2 
and TNFα when cells were stimulated with LPS under hypertonic conditions. As 
depicted in figure 13, synergy was not observed for CCL2 expression, while TNFα 
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was significantly increased by the combination of LPS and hypertonicity as compared 
to either of these conditions alone. This was found for both TNFα mRNA and protein 
expression. 
 
 
 
Figure 13: LPS and hypertonicity display synergy in the regulation of TNFα but not 
CCL2. miMCD cells were stimulated for 8 hrs with hypertonic (500 mOsm/kg H2O) NaCl 
concentrations (hatched bars), LPS (10ng/m) or both. mRNA expression of CCL2 and TNFα 
was measured by Taqman qPCR (upper panels). Data are normalized to ß2-microglobulin 
and expressed as mean CCL2 or TNFα mRNA level ± SEM relative to control unstimulated 
cells. In the lower panels CCL2 and TNFα production in the supernatants of the cells is 
depicted. *: P<0.01 (by one-way ANOVA), ns: not significant. 
 
3.6 NFAT5 is bound in the promoter of CCL2 and TNFα after stimulation  
We performed ChIP-analysis to assess if NFAT5 is present at the regulatory sites of 
the CCL2 and TNFα promoter when miMCD cells were challenged with LPS for 2 or 
4 hours. Quantification was performed by SYBR® green real-time PCR and expressed 
as percentage of the total not precipitated DNA and corrected for the non-specific 
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precipitation using rabbit IgG. Although, there were only able to pull-down a minimal 
amount of specific CCL2 or TNFα DNA, i.e. less than 1% of the input, we obtained 
reproducible assessment for CCL2 after NaCl stimulation and to a much lesser extent 
for TNFα after NaCl or LPS stimulation. Importantly, we were not able to pull-down 
NFAT5 at the CCL2 or TNFα promoter in cells that were not stimulated. (Figure 14) 
 
 
 
Figure 14: NFAT5 is associated with the CCL2 and TNFα promoter upon stimulation 
with LPS and hypertonic NaCl concentrations. miMCD cells were stimulated for 2 - (graph 
to the left) or 4 hours (graph to the right) with hypertonic (500mOSmo/Kg·H2O) NaCl 
concentrations or LPS (1µg/ml). ChIP analysis was performed using a polyclonal NFAT5 
antibody as described in the method section. The results of three independent experiments 
are expressed as mean % of the total input DNA ± SEM corrected for unspecific precipitation 
using normal Rabbit IgG.  
 
 
 
 
3.7 NFAT5 partly mediates CCL2 and TNFα expression in LPS stimulated 
murine splenocytes. 
Acute renal failure (ARF) in septic patients is frequently associated with polyuria and 
urine concentration defects [53]. It believed that endotoxemia decreases vasopressin 
V2 receptor and aquaporin-2 (AQP2) expression in vivo, which may account for the 
decrease in urine osmolality [59]. Moreover, endotoxemia may inactivate 
TonEBP/NFAT5 in a nitric oxide-dependent manner, causing down-regulation of 
renal medullary solute transport proteins and AQP2. We tested to what extent lack of 
NFAT5 affects the expression of pro-inflammatory cytokines in immune cells. To this 
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end, Cre+ NFAT5flx/flx mice were kept on a tamoxifen containing diet to obtain NFAT5-
/-
 mice. NFAT5 was successfully deleted only in mice positive for Cre and harboring 
the floxed NFAT5 gene (Figure 15).  
 
 
 
Figure 15: Tamoxifen treatment of Cre+ and Cre- NFAT5flx/flx mice. Cre+ and Cre- 
NFAT5flx/flx mice received a tamoxifin containing diet for 4 weeks. Genomic DNA was isolated 
from tail cuts before tamoxifin, and from splenocytes after tamoxifin treatment. PCR analysis 
was performed for Cre and NFAT5flx/flx as described in the methods. Note that NFAT5 was 
only detected in Cre- mice but not Cre+ mice in genomic DNA isolated from splenocytes after 
4 weeks of tamoxifin treatment. 
 
Splenocytes were isolated from of which after diet NFAT5 is knockout (n=6) and Cre+ 
NFAT5flx/flx  (n=6) and from control Cre- NFAT5flx/flx  (n=6)  mice respectively. The cells 
were stimulated with LPS (1µg/ml) for 12 hours and CCL2 and TNFα concentrations 
were assessed in the supernatants by ELISA. As depicted in figure 16, both TNFα, 
and to a larger extent CCL2 production was significantly lower in splenocytes 
obtained from NFAT5-/- mice.  
 
Figure 16: LPS mediated CCL2 and TNFα expression is impaired in murine 
splenocytes of NFAT5-/- mice. Cre+ and Cre- NFAT5flx/flx mice (n=6 for both groups) were 
fed for 4 weeks with a tamoxifen containing diet. Splenocytes were isolated and stimulated 
with LPS (1µg/ml) for 12 hours. Supernatants were harvested and assessed for production 
by ELISA. Results are expressed as mean CCL2 or TNFα production ± SEM from at least 
three independent experiments (*P<0.01). 
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3.8 Nuclear NFAT5 accumulation, CCL2 and TNFα expression in LPS 
stimulated murine macrophage cells (RAW264.7). 
Since we observed that CCL2 and TNFα production was impaired in NFAT5-/- mice, 
we studied nuclear NFAT5 accumulation and CCL2 and TNFα expression in more 
detail by making use of the murine macrophage cell line RAW 264.7. As depicted in 
figure 17, LPS led to a time dependent nuclear NFAT5 expression, which became 
evident 12 hrs after LPS stimulation (figure 17 upper panels). This was paralleled by 
an increased mRNA expression for CCL2, IL-1β and TNFα (figure 17 panels in the 
middle). To assess if cytokine production was partly mediated by NFAT5, siRNA 
experiments were carried out.  Knock-down of NFAT5 resulted in a decreased CCL2 
and TNFα production in supernatants of LPS stimulated RAW 264.7 cells (figure 17, 
lower panels). 
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Figure 17: Nuclear NFAT5 accumulation, CCL2 and TNFα expression in LPS stimulated 
murine macrophage cells (RAW264.7) (Upper panels): Westernblot for nuclear NFAT5 
expression in LPS (1µg/ml) stimulated RAW264.7 (Panels in the middle): mRNA expression 
of CCL2, IL-1ß, and TNFα was measured by Taqman qPCR. Data are normalized to ß2-
microglobulin and expressed as mean CCL2, IL-1ß or TNFα mRNA level ± SEM relative to 
control unstimulated cells (Lower panels):  TNFα and CCl2 production in culture 
supernatants obtained from NFAT5- and control siRNA transfected RAW264.7 12 hours after 
LPS (1µg/ml) stimulation were measured by ELISA.  Results are expressed as mean CCL2 
or TNFα production ± SEM. *: P<0.01 (by one-way ANOVA). 
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3.9 Influence of carbon monoxide (CO) on inflammatory mediators in LPS-
stimulated RAW264.7. 
There is ample evidence that carbon monoxide (CO) released from carbon monoxide 
releasing molecules (CORMs) is able to suppress inflammatory characteristics of 
murine macrophages [38, 60]. This is in part mediated via upregulation of HO-1 and 
inhibition of iNOS. To assess if these mediators are also influenced by CORMs that 
release CO directly intracellular, we made use of so-called esterase triggered (ET)-
CORMs. These ET-CORMs either contained acetate (rac4) or Monomethyl fumarate 
(MMF-CORM) as esterfunctionality. The latter was included in this study to create a 
so called bi-functional CORM, not only releasing CO but also the drug Monomethyl 
fumarate. As depicted in figure 18, LPS mediated iNOS expression was completely 
inhibited by MMF-CORM but not by MMF. HO-1 was strongly induced by MMF-
CORM and to a lesser extent by LPS, MMF or the combination of both. 
 
 
 
Figure 18: HO-1 and iNOS expression in murine macrophage cells (RAW264.7) Cells 
were cultured overnight in normal medium containing either LPS (1 µg/ml), MMF (12.5 µM) or 
MMF-CORM (12.5 µM). This was also carried out for the latter two conditions in the presence 
of LPS (1 µg/ml). Westernblot analysis was performed for iNOS, HO-1 and ß-actin to control 
for equal loading. The results a representative experiment from a total of 3 are shown.  
 
 
We next compared rac4, which only releases CO, MMF and MMF-CORM in a dose 
dependent manner, to test if MMF-CORM was superior to MMF or CO alone. As 
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depicted in figure 19, MMF-CORM was more superior compared to rac4 or MMF in 
inhibiting iNOS and inducing HO-1. 
 
 
 
Figure 19: Efficacy of rac4, MMF and MMF-CORM to inhibit iNOS and induce HO-1 
expression in murine macrophage cells (RAW264.7). Cells were stimulated overnight by 
LPS (1 µg/ml) in the presence of different concentrations (12.5-1.56 µM) of each rac4, MMF 
or MMF-CORM. Cells that were cultured overnight in normal medium served as control. 
Westernblot analysis was performed for iNOS, HO-1 and ß-actin to control for equal loading. 
The results a representative experiment from a total of 3 are shown. 
 
Next we assessed the influence of CO, released either from a simple ET-CORM 
(rac4) or from a bifunctional ET-CORM (MMF-CORM), on the expression of CCL-2 
and IL-1β mRNA in RAW264.7 cell stimulated by LPS for 12 hours (figure 20, upper 
panels). Likewise we tested if CCL2 and TNFα protein expression was influenced by 
these compounds. As demonstrated in figure 20, MMF-CORM strongly inhibited the 
mRNA expression of CCL-2 and IL-1β, suggesting a strong synergy between CO 
release and MMF. While this was also observed for CCL2 production in supernatants 
of RAW264.7 cells the inhibitory properties on TNFα production were less but still 
significant (figure 20, lower panels).  
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Figure 20: Efficacy of rac4, MMF and MMF-CORM to inhibit the expression of pro-
inflammatory cytokines in murine macrophage cells (RAW264.7). Cells were stimulated 
for 12 hours with LPS (1 µg/ml) in the presence of rac4, MMF or MMF-CORM (all at 12.5 
µM). Cells that were cultured in normal medium (M) or stimulated with LPS alone (-) served 
as control. Upper panels: mRNA expression of CCL2 and IL-1ß, TNFα was measured by 
Taqman qPCR. Data are normalized to ß2-microglobulin and expressed as mean CCL2, or 
IL-1ß mRNA level ± SEM relative to control unstimulated cells. The results a representative 
experiment from a total of 3 are shown. Lower panels: CCl2 and TNFα production in culture 
supernatants were measured by ELISA. Results are expressed as mean CCL2 or TNFα 
production ± SEM. *: P<0.01 (by one-way ANOVA). 
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3.10 Nuclear NFAT5 accumulation is inhibited by MMF-CORM in murine 
macrophage cells (RAW264.7) 
Since it has previously been reported that NFAT5 is essential for LPS mediated 
induction of iNOS, we investigated if CORMs prevent nuclear NFAT5 accumulation. 
While nuclear NFAT5 expression slightly increased after LPS stimulation, it was 
strongly suppressed by MMF-CORM but not rac4 or MMF (figure 21). 
 
 
 
Figure 21: Nuclear NFAT5 expression is inhibited by MMF-CORM in murine 
macrophage cells (RAW264.7). Westernblot for nuclear NFAT5 expression in LPS 
stimulated RAW264.7. Cells were stimulated for 12 hours with LPS (1 µg/ml) in the presence 
of rac4, MMF or MMF-CORM (all at 12.5 µM). Cells that were cultured in normal medium (M) 
or stimulated with LPS alone (-) served as control.  
 
3.11 MMF-CORM inhibits TNFα and IL-10 production in human monocytes 
Finally we studied if MMF-CORM is able to inhibit the expression of LPS stimulated 
monocytes. Because we have previously demonstrated [44], that release of CO from 
ET-CORM is partly depending on the position of the ester functionality within the iron 
tricarbonyl complex, in the present study we tested if this also holds true for the 
position of the methylfumarate ester. To this end, we used MMF-CORM-I 
(innerposition) and MMF-CORM-O (outerposition) (for both see Fig 5. in the 
introduction of this thesis) and compared the results with MMF alone. While MMF-
CORM-O strongly inhibited the production of TNFα and IL-10 in a dose dependent 
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manner, only IL-10 was inhibited and to a lesser extent as compared to MMF-CORM-
I. No influence of MMF alone was noted at equimolar concentration (figure 22).   
 
 
Figure 22: Influence of ester position in MMF-CORM on LPS mediated TNFα and IL-10 
production in human monocytes.  Human monocytes were isolated from buffy coat and 
stimulated for 12 hours with LPS (1 µg/ml) in the presence of MMF-CORM-O (12.5 - 3.125 
µM), MMF-CORM-I (25 and 12.5 µM) or MMF (25 and 12.5 µM). Cells that were cultured in 
normal medium (M) or stimulated with LPS alone (-) served as control. TNFα (A) and IL-10 
(B) production in supernatants was assessed by ELISA. Results are expressed as mean 
TNFα or IL-10 production ± SEM. *: P<0.01 (by one-way ANOVA). 
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4 DISCUSSION 
4.1 The role of NFAT5 in inflammation induced by hypertonicity stress 
The renal interstitial fluid contains high NaCl and urea concentrations to provide an 
osmotic gradient required for the concentration of urine. Hence, renal medullary cells 
are embedded in a hyperosmolar milieu that may cause damage to these cells. 
Under some conditions the interstitial fluid may reach osmolality up to 1200 
mOsmol/kg at the tip of the inner medulla. To avoid significant shriveling and 
shrinking that leads to cell death, cells elicit a genetic program of osmoregulation that 
gradually replaces electrolytes like Na+, Cl−, and K+ by small, uncharged organic 
osmolytes like sorbitol, betaine, and myo-inositol. This response is to a large extent 
mediated by the transcription factor NFAT5/TonEBP [61]. However NFAT5/TonEBP 
seems also to regulate the expression of pro-inflammatory cytokines such as CCL2 
and TNFα. Indeed our in vitro experiments clearly indicate that murine inner 
medullary collecting duct (iMCD) cells exposed to hyperosmolar stress (NaCl 100 
mM) upregulate mRNA expression of CCL2 and TNFα. The involvement of 
NFAT5/TonEBP in the regulation of CCL2 and TNFα was supported by the finding 
that NFAT5/TonEBP siRNA abrogated hyperosmolar stress induced expression of 
CCL2 and TNFα. Our results are in agreement with the findings of Kojima R et al. 
that hypertonicity also initiates a pro-inflammatory response in the rat epithelial NRK-
52E cells as reflected by the upregulation of CCL2 [58]. Moreover they demonstrate 
that the 5'-flanking region of the CCL2 gene indeed contains a hypertonicity-sensitive 
cis-acting element, i.e. a NFAT5/TonEBP binding site. Our data also demonstrate 
that NFAT5/TonEBP is recruited at the CCL2 promoter during hyperosmolar stress 
as evidenced by ChIP.  
It has been suggested that NFAT5/TonEBP and NF-κB act in concert to upregulate 
the expression of CCL2 and TNFα during hyperosmolar stress. Roth I et al [62] 
demonstrated a tonicity-dependent interaction between NFAT5 and NF-κB p65 that 
significantly enhances the transcription of NF-kB-regulated genes. Although a 
physical or functional interaction between both transcription factors was not 
investigated in our study, our data are in concordance to previous finding that 
hypertonicity indeed can induce inflammation in a NFAT5/TonEBP dependent 
manner. Hence it seems that apart from protecting cells against hyperosmolar stress  
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NFAT5/TonEBP may jeopardize these cells through the induction of pro-inflammatory 
cytokines. 
4.2 Activation of NFAT5/TonEBP by pro-inflammatory mediators  
In recent years evidence has accumulated suggesting that NFAT5/TonEBP not only 
is involved in osmoregulation but, independently of hypertonicity, also regulates 
inflammation. As reported by Lee.HH et al., NFAT5/TonEBP is contributing to the 
formation of the LPS-induced NF-kB enhancesome and as such is required for the 
recruitment of p300 in macrophages [63]. However, whether NFAT5/TonEBP is 
activated by inflammatory cytokines in renal iMCD cells is not well studied.  
Although our data indicate that nuclear NFAT5/TonEBP accumulation, as assessed 
by westernblot, does not occur in LPS or TNFα stimulated iMCD cells, 
NFAT5/TonEBP siRNA transfection significantly decreased CCL2 and TNFα 
expression upon LPS stimulation as compared to cells transfected with control 
siRNA. Moreover, ChIP revealed recruitment of NFAT5/TonEBP at the CCL2 and 
TNFα promoters upon LPS stimulation of iMCD cells, albeit to a lesser extent as 
compared to hypertonicity. It does seem that only minimal amounts of 
NFAT5/TonEBP are recruited, not sufficient enough to become detected by 
westernblot, yet functionally active in the regulation of CCL2 and TNFα. These data 
are consistent with the findings by Roth I et al. that LPS cannot induce nuclear 
NFAT5/TonEBP accumulation nor does it upregulate NFAT5/TonEBP mRNA 
transcription. Nonetheless there are some discrepancies between our findings and 
those of Roth I et al. while in the latter study it was found that NFAT5/TonEBP siRNA 
only downregulated TNFα but not CCL2 mRNA, our own study shows that both TNFα 
and CCL2 expression is affected in NFAT5/TonEBP siRNA transfected cells. This 
incongruity might be explained by differences between rat and murine collecting duct 
cells. It should however be emphasized that the data presented by Roth et al. also 
showed a reduced CCL2 expression but this did not reach statistical significance. 
Altogether, our finding demonstrated that LPS mediated TNFα and CCL2 expression 
in murine iMCD cells is partly regulated by NFAT5/TonEBP. Interestingly we did 
observe that concurrent stimulation of these cells with LPS and hyperosmolar 
concentrations of NaCl synergistically increased TNFα but not CCL2 expression. 
Thus, our data are compatible with the assumption that there is a cooperative action 
between NFAT5/TonEBP and NF-kB in response to inflammatory cytokines. 
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4.3 Splenocytes obtained from conditional NFAT5/TonEBP knockout mice 
display reduced cytokine responses upon LPS stimulation 
As conventional NFAT5/TonEBP knockout mice show high perinatal lethality due to 
impaired renal [64] and heart development [65] as well as impaired immune response 
[66], we studied the role of NFAT5/TonEBP in inflammatory responses by making 
use of conditional NFAT5/TonEBP knockout mice. In these mice the 4th 
NFAT5/TonEBP exon flanked by loxP sites allowing cre-mediated recombination of 
this allele [56]. NFAT5/TonEBPflx/flx mice were crossed with mice expressing the cre-
recombinase gene behind a tamoxifen inducible ubiquitin promoter. Our data showed 
that NFAT5/TonEBP was successfully deleted after 4 weeks of feeding a tamoxifen 
containing chow. Splenocytes isolated from these mice produced significantly lower 
amounts of pro-inflammatory cytokines after LPS stimulation as compared to 
NFAT5/TonEBP+/+ mice. These findings are in agreement with studies from Buxade 
M et al. [27] demonstrating that TNFα and CCL2 expression is down regulated in 
LPS stimulated NFAT5/TonEBP-/- BMDM. Likewise, Lee H [63] et al. showed that 
myeloid-specific deletion of NFAT5/TonEBP decreases systemic inflammation in 
sepsis. In in vivo experiments, LPS stimulation increased nuclear NFAT5/TonEBP 
expression in wild type macrophage, while in “haplo-insufficient” NFAT5/TonEBP+/- 
These and our own data collectively indicate that NFAT5/TonEBP plays an essential 
role in regulating cytokines responses upon LPS stimulation.  
Buxade M et al. postulated that in BDMDs NFAT5/TonEBP is constitutively bound to 
the TNF gene promoter regardless of TLR stimulation. This suggests that TNF might 
be an early primary response gene which is already associated with certain 
transcription factors and chromatin remodeling complexes under resting conditions 
[67, 68]. This pattern of constitutive NFAT5/TonEBP binding was also observed in 
other primary response target genes, i.e.IL1a, Traf1 and CCL2 [27]. Our own ChIP 
data showed that in murine iMCD cells NFAT5/TonEBP is not associated with the 
TNFα and CCL2 promoters under basal conditions. Hence it seems that constitutive 
NFAT5/TonEBP binding to promoters of pro-inflammatory genes might differ between 
tissues, while in response to LPS stimulation NFAT5/TonEBP seems to be recruited 
to these promoters irrespective of the cell-type.  
Apart from its role in inflammation, recent studies have also suggested a role in 
Coxsackievirus B3 (CVB3) induced myocarditis [69] and muscle regeneration [70].  
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4.4 Synergy between carbon monoxide (CO) and methyl fumarate  
A number of studies are currently performed to assess the potential clinical use of a 
variety of bifunctional gasotransmitters-based complexes. Naproxcinod is the first in a 
new class of anti-inflammatory agents known as CINODs (Cyclooxygenase-Inhibiting 
Nitric Oxide Donators) in development [71]. It is a nitrosylated naproxen derivative 
which can release nitric oxide and naproxen. As such, Naproxcinod retains the 
classic therapeutic profile of NSAID but prevents or reduces the adverse effect of 
NSAID, e.g. gastrointestinal bleeding [72] and increased blood pressure [73]. Similar 
to NO, in rodent models H2S also causes less NSAID mediated gastrointestinal 
damage and exerts various beneficial effects on cardiovascular and metabolic 
disorders [74-78]. 
In the present study we tested the biological efficacy of bifunctional esterase 
triggered CO releasing molecule (ET-CORM) with monomethyl fumarate (MMF) as 
ester functionality (MMF-CORM). The mechanism by which MMF-CORM releases 
carbon monoxide and fumarate consist of two steps. Firstly, intracellular esterases 
recognize the ester bond and hydrolyze the complex to release monomethyl fumarate 
and the remaining enol complex. This complex is oxidative labile and disintegrates by 
oxidation thereby releasing carbon monoxide, ferric iron and 2-cyclohexenone in a 
ratio of 3:1:1. Previously we demonstrated that the position of the ester moiety in ET-
CORMs determine the rate of CO release and thus affects it biological efficacy. In 
case the ester functionality is at the outer position of the cyclohexanone moiety the 
biological efficacy is in general increased. In analogy to this, we tested the efficacy of 
MMF-CORM with MMF either at the inner (MMF-CORM-I) or outer (MMF-CORM-O) 
position. In line with previous data using different ET-CORMs [43, 44], we also could 
show that MMF-CORM-O is more efficacious to inhibit IL-10 and TNFα expression in 
human monocytes in response to LPS stimulation. Importantly, our data showed that 
monomethyl fumarate itself did not suppress IL-10 and TNFα production, indicating 
that the anti-inflammatory effect of MMF-CORM is either due to the release of CO or 
CO is acting in concert with MMF to inhibit cytokine production. To explore these 
possibilities further, we compared the biological efficacies of a simple ET-CORM, i.e. 
rac-4, with MMF-CORM and MMF alone. Like rac-4, MMF-CORM-O has an ester 
functionality at the outer position but instead of MMF the ester being used as acetate. 
While rac-4 also inhibited TNFα, CCL2 and IL-1ß in LPS stimulated RAW264.7 cells, 
MMF-CORM-O was clearly more efficacious as compared to MMF alone or rac-4.  
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There are three types of nitric oxide synthase (NOS), i.e. endothelial - (eNOS), 
neuronal - (nNOS), and inducible nitric oxide synthase (iNOS). Endothelial nitric 
oxide synthase exists mainly in vascular endothelial cells while iNOS exists mainly in 
the cytoplasm of some inflammatory cells, e.g. macrophages. NO is produced mainly 
by eNOS catalysis, and also by the upregulation of iNOS expressions during 
inflammation. It has been reported that iNOS is induced to produce large amounts of 
NO by lipopolysaccharide, interleukin-1 (IL-1), and tumor necrosis factor (TNF), 
which play a role in the pathophysiological process of some diseases and in many 
inflammation and immune reactions [79]. Although it also acts as an effector 
molecule in innate immunity, overproduction of NO might be harmful and have been 
linked to many chronic inflammatory diseases. Based on animal experiments, 
selective inhibition of iNOS appears to be a promising means for the treatment of 
inflammatory diseases, although iNOS inhibitors have not yet shown to be beneficial 
in clinical trials [80, 81] [82]. 
Since it has been postulated that urinary concentration problems in septic patients 
might be due to overproduction of NO that subsequently leads to nitrosylation of 
NFAT5/TonEBP, we explored if a bifunctional CO releasing molecule may have a 
potential clinical benefit by inhibiting both iNOS expression and reducing the 
production of pro-inflammatory cytokines. MMF in conjunction with CO was studied to 
this end, since both compounds have been reported to inhibit iNOS and to reduce 
inflammation. Indeed our results show that iNOS expression was markedly inhibited 
by MMF-CORMs in LPS-stimulated RAW264.7.  
A variety of studies have revealed that the anti-inflammatory properties of carbon 
monoxide and CORMs are mediated via various signal transduction pathways. Lee.D 
et al. reported that CORM3 negatively regulates NLRP3 inflammasome activation in 
macrophages in a glycolysis-dependent manner [83]. Qin S et al. demonstrated that 
the nuclear factor-erythroid 2-related factor-2 (Nrf-2) is essential for the anti-
inflammatory effect of CORM2 as it could no longer reduce cytokine expression in 
septic Nrf-2 knock-out mice [38]. Choi E et al. showed that CORM3 suppresses the 
production of NO and IL-1β in LPS-activated murine macrophages via HO-1 
induction and inhibition of the NF-kB and STAT1 pathways [84].  
As mentioned above our data indicate that MMF-CORMs can suppress iNOS 
expression. Preliminary ongoing experiments suggest that MMF-CORM inhibits 
nuclear accumulation of NFAT5 in RAW264.7 cells. This assumption is supported by 
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the studies from Buxade M et al.[27] in which it has been found that NFAT5/TonEBP 
is a IKKβ-dependent regulator of iNOS expression. However, because rac-4 also 
inhibits iNOS expression but not nuclear NFAT5/TonEBP accumulation further 
experiment are required to address if indeed NFAT5/TonEBP is a genuine target of 
CO.   
Like already mentioned for cytokine expression, MMF-CORM were far more effective 
in inhibiting iNOS as compared to MMF or rac-4 alone. This was also found for the 
induction of HO-1. It thus seems that CO and MMF act synergistically to inhibit 
cytokine and iNOS expression and to induce the expression of HO-1.  
Although HO-1 is generally considered as a protective mediator due to its an anti-
oxidative and anti-inflammatory properties [85-87], recent studies have suggested 
that HO-1 might be harmful in triggering LPS-induced cardiac dysfunction in vivo [88]. 
This is based on the fact that HO-1 can interact with iNOS, thereby preventing 
lysosomal degradation of the iNOS protein and thus more NO-production leading to 
reactive nitrate species.   
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Figure 23 Putative signaling network of hyperosmolarity and LPS challenges 
and effect of MMF-CORMs treatment based on the results of the present study 
and previous findings. (1) Hypertonicity and LPS activate NF-kB and NFAT5 
translocation to the nucleus and initiates CCL2/TNFα transcription in the inner 
medullar collecting duct cell. (2) MMF-CORM may inhibit nuclear NFAT5 
accumulation and thereby downregulating cytokines and iNOS expression in 
macrophages. Also the upregulation of HO-1 may contribute to the anti-inflammatory 
properties. 
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5 CONCLUSION 
Tonicity-Responsive Enhancer Binding Protein (TonEBP), also known as nuclear 
factor of activated T cells 5 (NFAT5), is a ubiquitously expressed transcription factor 
involved in osmoregulation. As such TonEBP/NFAT5 regulates the expression of 
various osmoprotective genes including transporters and synthetic enzymes 
mediating the intracellular accumulation of small, compatible organic osmolytes. 
More recently studies have revealed that TonEBP/NFAT5 is also implicated in 
diabetic microvascular disease in the kidney, inflammatory bowel diseases, and 
hypertension. In addition to its osmoprotective and homeostatic roles, 
TonEBP/NFAT5 is also involved in regulating the expression of a variety of pro-
inflammatory genes in immune cells.  
Our data presented here reveal that TonEBP/NFAT5 not only is essential for CCL2 
and TNFα expression in miMCD cells subjected to hyperosmolar conditions, but also 
contributes to CCL2 and TNFα expression in response to LPS stimulation. With 
regard to hypertonicity, we observed that nuclear TonEBP/NFAT5 accumulation 
occurred in a time and dose dependent manner and was associated with increased 
CCL2 and TNFα mRNA and protein expression. In TonEBP/NFAT5 siRNA 
transfected miMCD cells CCL2 and TNFα mRNA and protein expression were 
significantly blunted after hyperosmolar stress. ChIP analysis indeed revealed 
TonEBP/NFAT5 binding to the CCL2 and TNFα promoters after stimulation. Like 
hyperosmolar stress also in LPS stimulated miMCD3 TonEBP/NFAT5 regulated 
CCL2 and TNFα expression, albeit that nuclear TonEBP/NFAT5 accumulation was 
not detected by westernblot analysis. Nonetheless both ChIP analysis and siRNA 
experiments revealed that small but functionally active amounts of TonEBP/NFAT5 
were recruited to the CCL2 and TNFα promoters and partly required for the 
expression of these cytokines 
In line with previous publications on immune cells we also demonstrated that, 
TonEBP/NFAT5 is important for the production of systemically released cytokines, 
e.g. TNFα and CCL2, in the course of sepsis. While LPS stimulation of splenocytes 
obtained from wild type mice resulted in profound expression of CCL2 and TNFα, in 
splenocytes obtained from conditionally TonEBP/NFAT5-/- mice this response was 
significantly diminished.  
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Since sepsis-induced urinary concentration defects are believed to be related to nitric 
oxide-dependent inactivation of TonEBP/NFAT5, we also explored the potential of 
carbon monoxide (CO) and monomethyl fumarate (MMF) to inhibit iNOS expression 
in murine macrophages. Both CO and MMF have been reported to inhibit iNOS 
expression and inhibit inflammatory mediators in vivo and vitro. CO (rac-4: esterase 
triggered (ET) CO releasing molecule (CORM)) and MMF were either applied alone 
or as so called bifunctional MMF-CORM. With respect to iNOS inhibition and HO-1 
induction we found that administration of MMF-CORM exert stronger effects than 
either application of ET-CORM (rac-4) or monomethyl fumarate (MMF) alone. As 
NFAT5 is the critical mediator of iNOS expression in macrophage, we further studied 
if inhibition of iNOS could be attributed to impaired nuclear TonEBP/NFAT5 
translocation. Preliminary ongoing experiments indeed suggest that MMF-CORM 
inhibits nuclear accumulation of NFAT5 in RAW264.7 cells. This finding is supported 
by the studies from Buxade M et al. in which it has been found that NFAT5/TonEBP 
is a IKKβ-dependent regulator of iNOS expression. However, because rac-4 also 
inhibits iNOS expression but not nuclear NFAT5/TonEBP accumulation further 
experiment are required to address if indeed NFAT5/TonEBP is a genuine target of 
CO.  
In conclusion, this study revealed that NFAT5 is an essential mediator of 
inflammation in medullar collecting duct cells that are either challenged by 
hyperosmolar stress or LPS. Bifunctional MMF-CORM may be of clinical relevance in 
the treatment of sepsis induced acute kidney injury as it not only strongly diminishes 
the expression of systemically released pro-inflammatory cytokines, but also inhibits 
iNOS expression. The latter might be important for preventing sepsis induced urinary 
concentration defects. 
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